VIVSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
VivoSim Labs, INC.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.16+0.00 (+0.38%)
Close on Oct 19, 2026
- Market cap
- $825.22K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.4025 (−93.85%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
VivoSim Labs, INC. saw revenue fall 21.1% to $112.00K over the twelve months to Jun 30, 2026. Free cash flow was -$10.12M.
Revenue
$112.00K
-21.1% vs. a year earlier
Operating income
-$11.33M
TTM Q1 2027
Free cash flow
-$10.12M
TTM Q1 2027
EPS, diluted
-$4.45
TTM Q1 2027
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $825.22K
- P/E ratio
- –
- Price to sales
- 7.37
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -1226.71%
Fundamentals
- Revenue
- $112.00K
- Net income
- -$12.34M
- EPS, diluted
- -$4.45
- Free cash flow
- -$10.12M
- Book value per share
- -$0.45
- Diluted shares
- 5M
Fifteen years at a glance
Fiscal years 2010 to 2026 and trailing twelve months, USD
Revenue
$112.00K-21.1% YoY
Gross profit
–
Operating income
-$11.33M
Net income
-$12.34M
EPS, diluted
-$4.45
Free cash flow
-$10.12M
Reported periodTrailing twelve months